What is Leerink Partnrs’ Forecast for FOLD Q2 Earnings?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Equities research analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for Amicus Therapeutics in a research report issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz anticipates that the biopharmaceutical company will post earnings per share of ($0.01) for the quarter. The consensus estimate for Amicus Therapeutics’ current full-year earnings is ($0.04) per share. Leerink Partnrs also issued estimates for Amicus Therapeutics’ Q4 2025 earnings at $0.07 EPS and FY2025 earnings at $0.04 EPS.

Several other research analysts have also weighed in on the company. Bank of America increased their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. Morgan Stanley reiterated an “equal weight” rating and set a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research report on Monday, January 13th. Finally, Guggenheim lifted their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $16.88.

Amicus Therapeutics Stock Performance

Amicus Therapeutics stock opened at $9.54 on Tuesday. The firm has a 50 day simple moving average of $9.64 and a 200-day simple moving average of $10.52. The stock has a market cap of $2.85 billion, a price-to-earnings ratio of -28.06, a price-to-earnings-growth ratio of 1.51 and a beta of 0.62. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. Amicus Therapeutics has a 1-year low of $8.78 and a 1-year high of $14.03.

Insider Transactions at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,901 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total transaction of $98,762.50. Following the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $11,083,175. This represents a 0.88 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders have sold 22,901 shares of company stock valued at $259,863. 2.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Amicus Therapeutics

Several institutional investors have recently modified their holdings of FOLD. Envestnet Asset Management Inc. boosted its holdings in Amicus Therapeutics by 3.7% in the second quarter. Envestnet Asset Management Inc. now owns 450,823 shares of the biopharmaceutical company’s stock valued at $4,472,000 after purchasing an additional 16,263 shares during the period. Mutual of America Capital Management LLC raised its position in Amicus Therapeutics by 24.2% in the 2nd quarter. Mutual of America Capital Management LLC now owns 250,293 shares of the biopharmaceutical company’s stock valued at $2,483,000 after purchasing an additional 48,802 shares in the last quarter. Blair William & Co. IL boosted its stake in shares of Amicus Therapeutics by 15.2% in the 2nd quarter. Blair William & Co. IL now owns 47,254 shares of the biopharmaceutical company’s stock valued at $469,000 after buying an additional 6,237 shares during the period. Inspire Investing LLC grew its position in shares of Amicus Therapeutics by 13.3% during the second quarter. Inspire Investing LLC now owns 35,242 shares of the biopharmaceutical company’s stock worth $350,000 after buying an additional 4,148 shares in the last quarter. Finally, Sei Investments Co. increased its stake in shares of Amicus Therapeutics by 8.7% during the second quarter. Sei Investments Co. now owns 242,131 shares of the biopharmaceutical company’s stock worth $2,403,000 after buying an additional 19,416 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.